This test measures cross-linked peptide sequences of Type 1 collagen, called deoxypyridinoline (Dpd), that makes up the bone matrix excreted unmetabolised in urine.
These are direct products of the breakdown of bone, and by measuring Dpd in the urine, can help identify accelerated bone breakdown and predict the probability of bone loss without appropriate therapy.
The test can also help monitor whether therapy is working and measure a patient’s response to therapy within three months. A pre-therapy assessment is recommended if monitoring therapy with this test.
Sample requirements: 1 x first morning urine sample
Patient requirements: It is not necessary to discontinue nutritional supplements prior to this test, as abnormalities found will reveal special needs not met by recent dietary supplement intake.
Product code: END18